Opioid-induced Constipation
📧 Sign up to get email alerts when something new happens for Opioid-induced Constipation.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-19EMA Authorised: Relistor (methylnaltrexone bromide) — Bausch Health Ireland Limited
The EMA authorised Relistor (methylnaltrexone bromide) by Bausch Health Ireland Limited for opioid-induced constipation. The decision date w…
-
EMA approval · 2025-12-10EMA Authorised: Rizmoic (naldemedine tosilate) — Shionogi B.V.
The European Medicines Agency has authorised Rizmoic (naldemedine tosilate) by Shionogi B.V. for constipation. It addresses opioid-induced c…
-
FDA approval · 2025-07-15FDA Approved: SYMPROIC — Supplemental Application (BioDelivery Sciences International Inc)
The FDA approved a supplemental application for Symproic (naldemedine) from BioDelivery Sciences International Inc, authorizing changes to t…
-
EMA approval · 2025-04-11EMA Authorised: Moventig (naloxegol oxalate) — Grunenthal GmbH
EMA authorised Moventig (naloxegol oxalate) from Grunenthal GmbH for the treatment of constipation, including opioid-induced constipation. T…
-
FDA approval · 2025-01-02FDA Approved: LUBIPROSTONE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original generic application for lubiprostone to treat chronic idiopathic constipation, opioid-induced …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-23FDA Approved: LUBIPROSTONE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original application for lubiprostone from Zydus Pharmaceuticals USA Inc., establishing a generic version of Lubiprostone. …
-
FDA approval · 2020-11-30FDA Approved: LUBIPROSTONE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
The FDA approved a supplemental application for Lubiprostone submitted by Dr. Reddy's Laboratories, updating labeling under NDA 021908.
-
FDA approval · 2020-04-13FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)
The FDA approved a supplemental application for Movantik (naloxegol oxalate) submitted by RedHill Biopharma Ltd.
-
FDA approval · 2018-04-26FDA Approved: LUBIPROSTONE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for Lubiprostone filed by Dr. Reddy's Laboratories Inc.
-
FDA approval · 2018-03-14FDA Approved: RELISTOR — Supplemental Application (Salix Pharmaceuticals, Inc.)
FDA approved a supplemental application for Relistor (methylnaltrexone bromide) from Salix Pharmaceuticals, Inc.
-
FDA approval · 2018-02-28FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)
FDA approved a supplemental application for MOVANTIK (naloxegol oxalate) filed by RedHill Biopharma Ltd.
-
FDA approval · 2018-01-24FDA Approved: SYMPROIC — Supplemental Application (BioDelivery Sciences International Inc)
FDA approved a supplemental application for Symproic (nalmefene) submitted by BioDelivery Sciences International Inc.
-
FDA approval · 2017-08-01FDA Approved: RELISTOR — Supplemental Application (Salix Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Relistor (methylnaltrexone bromide) from Salix Pharmaceuticals, Inc.
-
FDA approval · 2017-08-01FDA Approved: SYMPROIC — Supplemental Application (BioDelivery Sciences International Inc)
FDA approved a supplemental application for Symproic (naldemedine) from BioDelivery Sciences International Inc.
-
FDA approval · 2017-08-01FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)
The FDA approved a supplemental application for Movantik (naloxegol oxalate) submitted by RedHill Biopharma Ltd.
-
FDA approval · 2017-05-16FDA Approved: RELISTOR — Supplemental Application (Salix Pharmaceuticals, Inc.)
The FDA approved a supplemental application for RELISTOR (methylnaltrexone bromide) from Salix Pharmaceuticals, expanding its labeling relat…
-
FDA approval · 2017-05-16FDA Approved: RELISTOR — Supplemental Application (Salix Pharmaceuticals, Inc.)
FDA approved a supplemental application for Relistor (methylnaltrexone bromide) by Salix Pharmaceuticals, expanding its labeling for opioid-…
-
FDA approval · 2017-03-23FDA Approved: SYMPROIC — Original Application (BioDelivery Sciences International Inc)
The FDA approved Symproic (naldemedine) from BioDelivery Sciences International, granting original NDA approval NDA208854 for the treatment …
-
FDA approval · 2016-10-11FDA Approved: LUBIPROSTONE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for Lubiprostone from Dr. Reddy's Laboratories Inc., typically reflecting updates to labeling or ind…
-
FDA approval · 2016-08-22FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)
FDA approved a supplemental application for Movantik (naloxegol oxalate) from RedHill Biopharma Ltd.
-
FDA approval · 2016-07-22FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)
The FDA approved a supplemental application for MOVANTIK (naloxegol oxalate) from RedHill Biopharma Ltd, potentially expanding or updating t…
-
FDA approval · 2016-07-19FDA Approved: RELISTOR — Original Application (Salix Pharmaceuticals, Inc.)
FDA approved Relistor (methylnaltrexone bromide) as an original NDA submission by Salix Pharmaceuticals, marking its regulatory clearance fo…
-
FDA approval · 2015-04-30FDA Approved: RELISTOR — Supplemental Application (Salix Pharmaceuticals, Inc.)
FDA approved a supplemental application for Relistor (methylnaltrexone bromide) from Salix Pharmaceuticals, expanding its labeling for opioi…
-
FDA approval · 2014-09-16FDA Approved: MOVANTIK — Original Application (RedHill Biopharma Ltd)
FDA approved Movantik (naloxegol oxalate) through an Original Application for the treatment of opioid-induced constipation in adults with ch…
-
FDA approval · 2013-08-23FDA Approved: RELISTOR — Supplemental Application (Salix Pharmaceuticals, Inc.)
The FDA approved a supplemental application for RELISTOR (METHYLNALTREXONE BROMIDE) from Salix Pharmaceuticals, adding an indication/label u…